Navigation Links
Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
Date:1/19/2009

MONT-SAINT-GUIBERT, Belgium, January 19 /PRNewswire/ --

- New Funds to Drive Clinical Development of C-Cure(R), a Second-Generation Cell-Based Therapy for Heart Failure

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, has raised EUR7.2 million in a successful Series B fund raising round. The new funds, which have come from a range of new and existing investors, will be used to finance the clinical development of the Company's lead product. C-Cure is a unique therapy that allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle. C-Cure holds the promise for a treatment that could fundamentally change the future of heart failure patients, one of the world's largest medical needs. The Company plans to enrol shortly approximately 240 patients in a clinical trial with C-Cure to evaluate its potential in the treatment of heart failure.

Cardio3 BioSciences was founded in 2007 by clinicians from the Cardiovascular Center in Aalst, Belgium with a vision of using a cell-based approach for the treatment of heart disease. The Company is led by a senior management team with extensive experience in developing and commercialising pharmaceutical and medical technologies and leverages proprietary technology developed by researchers from Mayo Clinic, a shareholder in the company. Following the successful B series fund raising, Cardio3 BioSciences has added new investors including the Belgium-based investment group Life Science Research Partners, a Luxemburg-based venture capital firm, Hunza Ventures II that focuses on life sciences, IT and cleantech industries, and Grifols, a Spanish holding company specialising in the pharmaceutical hospital industry. Other new investors were not disclosed.

In parallel with this equity fund
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... , Aug. 27, 2015   Women Grow , the fastest-growing ... is partnering with the Cannabis World Congress & Business ... to produce 15 business-focused educational sessions. CWCBExpo in LA will ... Angeles Convention Center in Los Angeles, ... the West Coast for the marijuana industry. The ...
(Date:8/27/2015)... Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... corrected the multiple inaccuracies in the press release ... the recent rulings from the Patent Trial and ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
... 2011 Boston Scientific Corporation (NYSE: BSX ) ... to fund the "Donald S. Baim, M.D., ,75 Scholarship Fund" ... the late interventional cardiology pioneer and Yale School of Medicine ... Officer from 2006 until 2009, when he died unexpectedly. ...
... Calif., Feb. 15, 2011 Viral Genetics, Inc. (Pink Sheets: ... M. Karen Newell Rogers and Advisor Mr. Richard Gerstner will ... for Lyme, Inc. The award presentation is set for the ... Dr. Newell Rogers is being recognized for her research on ...
Cached Medicine Technology:Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 2Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 3Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 4Viral Genetics' Researcher and Advisor Set to Share Award 2Viral Genetics' Researcher and Advisor Set to Share Award 3
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... has joined the company as the new Global Communications Director for InHealth Media. ... relations experience having spent the last 16 years doing on-air television, producing shows, ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ... assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products International. ... your goals. Kathleen graduated from Florida State University with a Bachelor of ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent for Clinical ... p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed consent ... , Clinical trial sites can now use audio, video and interactivity to educate ...
(Date:8/29/2015)... ... 29, 2015 , ... Targeted therapies, made possible by a ... patients, according to a newly published report. Surviving Mesothelioma has more on the ... , The authors of the new paper focus on several types of targeted ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... April, Recommending Systematic Changes, WASHINGTON, July 2 ... for America,s Health (TFAH), expressed,concern about a new ... last month,s,nationwide salmonella outbreak. Approximately 530,000 pounds of ... is underway to take suspect,beef off market shelves. ...
... LAVAL, QC, July 2 /PRNewswire-FirstCall/ - Labopharm Inc. ... submitted a complete response to,the Food and Drug ... M.D., the FDA,s Deputy Director, Center for Drug ... the regulatory path towards,potential U.S. approval of the ...
... NASHVILLE, Tenn., July 2 Ambulatory Services of,America, ... in the,St. Louis, Missouri area from Affiliated Hospitals ... venture between St. Luke,s,Episcopal-Presbyterian Hospitals and St. John,s ... provided services to more than 300 patients,through the ...
... Foundation announced the election today of Jean Howard ... City, Michigan, is finishing her fifth year on,the ... first Alliance,representative to be President of the Foundation. ... Treasurer, Finance,Committee Chair, Secretary, Bylaws Committee member, HAP ...
... retailers nationwide and ... http://www.caribbean-sol.com , ... ) biodegradable sunscreen, Caribbean Sol,SolGuard SPF 25 and Kids ... Group,s Skin Deep Cosmetics Safety Database,( http://www.cosmeticsdatabase.com )., ...
... anesthesia, number of instruments inserted into canal , , WEDNESDAY, July ... surgical treatment of ear infections safer and faster has been ... which combines three of the tools used in the surgical ... clinical trials. , Each year in the United States, about ...
Cached Medicine News:Health News:Trust for America's Health: New E. Coli Outbreak, Confusion Around Salmonella Show Food Safety System Remains Broken 2Health News:Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol 2Health News:Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri 2Health News:AMA Foundation Names Jean Howard President 2Health News:Caribbean Sol Biodegradable Sunscreen Gets Strong Safety Rating From Environmental Working Group 2Health News:New Ear Tube Device Helps Treat Infections Faster 2
Convenience, Protection, Comfort and Security -- FirstChoice pouches are your product of choice if you are looking for the convenience of a one-piece pouch that is either cut-to-fit or pre-cut to you...
Inquire...
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Medicine Products: